1. Agrawal, S., 2003. Biopharmaceutics and pharmacokinetics of rifampicin: implications in performance and evaluation of anti-tuberculosis fixed dose combination formulations. Ph.D. Thesis, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, India.
2. Blomberg, B., Evans, P., Phanouvong, S., Nunn, P., 2002. Informal consultation on 4-drug fixed dose combinations (4FDCs) compliant with the WHO model list of essential drugs, 15–17 August 2001. World Health Organization, Geneva, WHO/CDS/TB/2002.299.
3. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis;Blomberg;Bull. WHO,2001
4. Fourie, B., Pillai, G., McIlleron, H., Smith, P., Panchagnula, R., Ellard, G., 1999. Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to single drug reference preparations administered in loose combination (Model Protocol). World Health Organization, WHO/CDS/TB/99.274.
5. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units 1946–1986 with relevant subsequent publications;Fox;Int. J. Tuberc. Lung Dis.,1999